KWANG DONG PHARMACEUTICAL CO., LTD.
🇹🇼Taiwan
- Country
- 🇹🇼Taiwan
- Ownership
- Public
- Established
- 1963-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.ekdp.com
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Kwang Dong Pharmaceutical co., ltd.
- Target Recruit Count
- 193
- Registration Number
- NCT04943068
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Prospective, Single-centre, Open-label Study to Confirm the Efficacy and Safety of Vitamin D3 B.O.N. Intramuscular Injection in Adults With Vitamin D Deficiency
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Kwang Dong Pharmaceutical co., ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT03233295
To Evaluate the Safety, Tolerability, PK, PK-PD Relation of KD101 in the Fed State in Obese or Overweight Subjects
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Kwang Dong Pharmaceutical co., ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT02462031
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Prospective, Multi-center Study to Evaluate the Efficacy and Safety of Vitamin D3 B.O.N. Intramuscular Injection in Adults With Vitamin D Deficiency
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- Kwang Dong Pharmaceutical co., ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT02443246
Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male Subjects
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2014-08-12
- Lead Sponsor
- Kwang Dong Pharmaceutical co., ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT01979380
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2014-03-12
- Lead Sponsor
- Kwang Dong Pharmaceutical co., ltd.
- Target Recruit Count
- 235
- Registration Number
- NCT01458197
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
© Copyright 2024. All Rights Reserved by MedPath